Ironwood Pharmaceuticals (IRWD) Total Debt (2012 - 2026)

Ironwood Pharmaceuticals has disclosed Total Debt across 15 years of filings, most recently posting $385.0 million for Q2 2026.

• In Q2 2026, Total Debt fell 34.11% year-over-year to $385.0 million; the TTM figure through Jun 2026 stood at $385.0 million (down 34.11% YoY), while the FY2025 annual figure was $584.7 million, up 51.86% from the prior year.
• Total Debt came in at $385.0 million for Q2 2026 at Ironwood Pharmaceuticals, down from $584.9 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $599.1 million in Q2 2023 to a low of $1000.0 in Q3 2022.
• Average Total Debt over 5 years is $384.5 million, with a median of $425.0 million recorded in 2024.
• Year-over-year, Total Debt sank 100.0% in 2022 and soared 52432000.0% in 2023.
• Over 5 years, Total Debt stood at $19000.0 in 2022, then soared by 2629163.16% to $499.6 million in 2023, then fell by 22.93% to $385.0 million in 2024, then soared by 51.86% to $584.7 million in 2025, then plunged by 34.15% to $385.0 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $385.0 million in Q2 2026, $584.9 million in Q1 2026, and $584.7 million in Q4 2025.